Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) announced that Norpace CR (disopyramide phosphate; Pfizer) controlled-release 100mg is currently in shortage.
Norpace CR 100mg capsules in 100- and 500-count bottles are currently unavailable due to a manufacturing delay; it is estimated to be out of stock and on backorder until the third quarter of 2015. While Norpace CR 150mg capsules in 100- and 500-count bottles are available, it is possible that this strength will be in shortage through the third quarter of 2015.
RELATED: FDA: Hypertension Tx Currently in Shortage
Norpace 100mg and 150mg capsules in 100-count bottles are not affected by the shortage and are available. Clinicians are advised to use their judgment and expertise to determine appropriate treatment options for their patients.
Norpace and Norpace CR are indicated for the treatment of documented life-threatening ventricular arrhythmias.
For more information visit FDA.gov.
